Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Directorate Change

8 Mar 2005 11:15

ReGen Therapeutics PLC08 March 2005 ReGen Therapeutics Plc REGEN THERAPEUTICS PLC APPOINTS ADDITIONAL NON-EXECUTIVE DIRECTOR 8 March 2005 ReGen Therapeutics Plc (the 'Company') today announces that it has appointed DrPeter Garrod to be a non-executive director of the Company with immediateeffect. Peter Garrod commented "I was introduced to a natural product for the potentialtreatment of Alzheimer's disease in 1998. I have followed and supported ReGenwith absolute dedication in their quest for a treatment for this debilitatingcondition. I have always been at the forefront of advances in technology in my own fieldand feel that my input will enhance the progress and development of ReGen andwill endeavour to support the best interests of the shareholders". Percy Lomax the Chairman and Chief Executive of the Company commented "I welcomePeter Garrod to the Board. As a major shareholder his backing for the Board isimportant, but I believe that his scientific and business experience, togetherwith his enthusiasm to produce a better treatment for Alzheimer's disease willbe major assets to ReGen". Dr Garrod was born on 24th October 1950 and was educated at the London Hospital,part of the University of London. He graduated with a BDS and is a LDS of theRoyal College of Surgeons. He has been the Senior Partner of the Bower DentalCentre, which specialises in advanced dental cosmetic surgery, for the last 18years. There are no details to be disclosed pursuant to paragraphs (f)(iii) to(viii) of Schedule 2 to the AIM Rules. Dr Garrod currently holds and is beneficially interested in 36,000,000 ordinaryshares of the Company representing 10.5% of the current issued share capital ofthe Company. For further information, please contact:Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.